Omalizumab, a novel anti-IgE therapy in allergic disorders

Bibliography

• HOLGATE ST: The cellular and mediator basis of asthma in relation to natural history. Lancet (1997) 350\(Suppl. 2):S115–119.
   Google Scholar
• BARNES PJ: Efficacy of inhaled corticosteroids in asthma. j Allergy Clin. Immunol (1998) 102:531–538.
   PubMed Web of Science ®Google Scholar
• SAMPSON AP, RORKE S: Combination therapy with anti-mediator drugs in allergic disease. Chu. Exp. Allergy (2001) 31:11–17.
   PubMed Web of Science ®Google Scholar
• BABU KS, HOLGATE ST: Potential and novel therapies for asthma. j Assoc. Physicians India (2000) 48:1096–1102.
   PubMedGoogle Scholar
• ISHIZAKA K, ISHIZAKA T: Identification of gamma-E-antibodies as a carrier of reaginic activity. I Immunol (1967) 99:1187–1198.
   PubMed Web of Science ®Google Scholar
• JOHANSSON SG, BENNICH H: Immunological studies of an atypical (myeloma) immunoglobulin. Immunology (1967) 13:381–394.
   PubMed Web of Science ®Google Scholar
• OETTGEN HC, GEHA RS: IgE regulation and roles in asthma pathogenesis. j Allergy Chu. Immunol (2001) 107:429–440.
   PubMed Web of Science ®Google Scholar
• JOHANSSON SG: Discovery and development of IgE assays. Clin. Exp. Allergy (1997) 27\(Suppl. 1):60–63.
   Google Scholar
• BENNICH HH, ISHIZAKA K, JOHANSSON SGO et al: Immunoglobulin E, a new class of human immunoglobulin. Bull. WHO (1968) 38:151–152.
   PubMed Web of Science ®Google Scholar
• BRADDING P, HOLGATE ST: Immunopathology and human mast cell cytokines. Grit. Rev OricoldHematol. (1999) 31:119–133.
   PubMed Web of Science ®Google Scholar
• HUAGAARD L, IVERSEN M, DAHL R: Predictors of early- and late-phase reactions to bronchial allergen challenge. Allergy (1997) 52:999–1004.
   PubMed Web of Science ®Google Scholar
• ZWEIMAN B: The late-phase reaction: roleof IgE, its receptor and cytokines. Curr. Opin. Immunol (1993) 5:950–955.
   PubMed Web of Science ®Google Scholar
• BABU KS, ARSHAD SH: IgE- A marker of late asthmatic response? Clin. Exp. Allergy (2001) 31:182–187.
   Web of Science ®Google Scholar
• BURROWS B, MARTINEZ FD, HALONEN M et al.: Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl. J. Med. (1989) 320:271–277.
   PubMed Web of Science ®Google Scholar
• PEAT JK, TOELLE BG, DERMAND J et al.: Serum IgE levels, atopy, and asthma in young adults: results from a longitudinal cohort study. Allergy (1996) 51:804–810.
   PubMed Web of Science ®Google Scholar
• POSTMA DS, BLEECKER ER, AMELUNG PJ et al.: Genetic susceptibility to asthma-bronchial hyper-responsiveness coinherited with a major gene for atopy. N Engl. J. Med. (1995) 333:894–900.
   PubMed Web of Science ®Google Scholar
• PEARCE N, PEKKANEN J, BEASLEY R: How much asthma is really attributable to atopy? Thorax (1999) 54:268–272.
   PubMed Web of Science ®Google Scholar
• YING S, HUMBERT M, MENG Q et al: Local expression of germline gene transcripts and RNA for the heavy chain of IgE in the bronchial mucosa in atopic and nonatopic asthma. j Allergy Clin. Immunol (2001) 107:686–692.
   PubMed Web of Science ®Google Scholar
• ••An excellent study that provides evidencefor local IgE synthesis from bronchial mucosa of both tropic and non-tropic asthmatics thereby suggesting a role for IgE in non-tropic asthma.
   Google Scholar
• PAWANKAR R, YAMAGISHI S, YAGI T: Revisiting the roles of mast cells in allergic rhinitis and its relation to local IgE synthesis. Am. J. Rhino]. (2000) 14:309–317.
   PubMedGoogle Scholar
• BONNEFOY JY, AUBRY JP, GAUCHAT JF et al: Receptors for IgE. Curr. Opin. Immunol (1993) 5:944–949.
   PubMed Web of Science ®Google Scholar
• BONNEFOY JY, LECOANET-HENCHOZ S, GAUCHAT JF et al: Structure and functions of CD23. mt. Rev Immunol (1997) 16:113–128.
   PubMedGoogle Scholar
• PAWANKAR R, OKUDA M, YSSEL H et al.: Nasal mast cells in perennial allergic rhinitics exhibit increased expression of the Fc epsilonRI, CD4OL, IL-4, and IL-13, and can induce IgE synthesis in B cells. j Chu. Invest. (1997) 99:1492–1499.
   PubMed Web of Science ®Google Scholar
• SIHRA BS, KON OM, GRANT JA et al: Expression of high-affinity IgE receptors (Fc epsilon RI) on peripheral blood basophils, monocytes, and eosinophils in atopic and nonatopic subjects: relationship to total serum IgE concentrations. j Allergy Clin. Immunol (1997) 99:699–706.
   PubMed Web of Science ®Google Scholar
• YAMAGUCHI M, LANTZ CS, OETTGEN HC et al: IgE enhances mouse mast cell Fc(epsilon)RI expression in vitro and in vivo: evidence for a novel amplification mechanism in IgE-dependent reactions. 1. Exp. Med. (1997) 185:663–672.
   PubMed Web of Science ®Google Scholar
• KOLBINGER F, SALDANHA J, HARDMAN N et al.: Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies. Prot. Eng. (1993) 6:971–980.
   PubMedGoogle Scholar
• •One of the early papers to report the humanisation of the mouse anti-IgE antibody.
   Google Scholar
• Cl-LANG TW: The pharmacological basis of anti-IgE therapy. Nat. Biotech. (2000) 18:157–162.
   PubMed Web of Science ®Google Scholar
• ••An excellent review looking into thedevelopment of anti-IgE as a therapeutic strategy.
   Google Scholar
• HOLLOWAY JA, HOLGATE ST, SEMPER AE: Expression of high-affinity IgE receptor on peripheral blood dendritic cells. Differential binding of IgE in atopic asthma. 1. Allergy OM. Immuriol (2001) (In Press).
   Google Scholar
• PRESTA LG, LAHR SJ, SHIELDS R et al: Humanization of an antibody directed against IgE. 1. Immunology (1993) 151:2623–2632.
   PubMed Web of Science ®Google Scholar
• HAAK-FRENDSCHO M, ROBBINS K, LYON R etal.: Administration of an anti-IgE antibody inhibits CD23 expression and IgE production in vivo. Immuriol (1994) 82:306–313.
   Google Scholar
• LIU J, LESTER P, BUILDERS et al: Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry (1995) 34:10474–10482.
   PubMed Web of Science ®Google Scholar
• FOX JA, HOTALING TE, STRUBLE C et al.: Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. I Pharmacol Exp. Ther. (1996) 279:1000–1008.
   PubMed Web of Science ®Google Scholar
• CASALE TB, BERNSTEIN IL, BUSSE WW etal.: Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. j Allergy CBI]. Immuriol (1997) 100:110–121.
   Google Scholar
• MACGLASHAN DW, BOCHNER BS, ADELMAN DC et al: Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. 1. Immuriol (1997) 158:1438–1445.
   Google Scholar
• TOGIAS A, CORREN G, SHAPIRO et al:Anti-IgE treatment reduces skin test reactivity. I Allergy OM. Immuriol (1998) 101:s171.
   PubMed Web of Science ®Google Scholar
• COYLE A, WAGNER K, BERTRAND et al.: Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: inhibition by a non-anaphylactogenic anti-IgE antibody. 1. Exp. Med. (1996) 183:1303–1310.
   Google Scholar
• •Study demonstrating that IgE-dependent mechanisms are important in the induction of a Th2 immune response and neutralisation of IgE, with a non-anaphylactogenic anti-IgE mAb may provide a novel therapeutic approach to the treatment of allergic airway disease.
   Google Scholar
• FAHY JV, FLEMING HE, WONG H et al.: The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am. 1. Respir. Grit. Care Med. (1997) 155:1828–1834.
   Google Scholar
• ••An interesting study showing the role IgEcould play in both early and late asthmatic responses providing evidence for the role of IgE in the late phase responses.
   Google Scholar
• BOULET LP, CHAPMAN KR, COTE J et al.: Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am. 1. Respir. Grit. Care Med. (1997) 155:1835–1840.
   Google Scholar
• NOGA 0, HANF G, KIRCHHOF et al: Treatment with omalizumab (rhuMAb-E25), a monoclonal anti-IgE antibody induces effective changes in subjects with allergic asthma. Eur. Respir. 1 (2001) 18:37s.
   Google Scholar
• MILGROM H, FICK RB, SU JQ et al: Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl. 1. Med. (1999) 341:1966–1973.
   PubMed Web of Science ®Google Scholar
• SOLER M, MATZ J, TOWNLEY R etal.: rhuMAb-E25, a novel therapy for the treatment of allergic asthma (AA). Eur. Respir: J. (2000) 16:10s.
   Google Scholar
• BUSSE W, CORREN J, LANIER BQ et al.: rhuMAb-E25 (E25), a novel therapy for the treatment of allergic asthma. 1. Allergy CBI]. Immuriol (2000) 105:5. Abstract.
   Google Scholar
• MILGROM H, NAYAK A, BERGER W et al.: The efficacy and safety of rhuMAb-E25 in children with allergic asthma. I Allergy CBI]. Immuriol (2000) 105:4.
   Google Scholar
• O'BRIEN JA, FOX H, THIRWELL J: Omalizumab (Xolair 9 increased the time to first exacerbation in patients with moderate-to-severe asthma compared with placebo. ..1 Allergy OM. Immuriol (2001) 107:s107.
   Google Scholar
• CHUNG F, FOX H, THIRWELL J: Omalizumab (Xolair 9 increases the number of asthma controlled days in moderate-to-severe asthma patients compared to placebo. I Allergy Clin. Immuriol (2001) 107:s112.
   Web of Science ®Google Scholar
• SOLER M, BUHL R, BENSCH 0 et al: Omalizumab (Xolair®, rhuMAb-E25) Treatment reduces inhaled corticosteroid use in moderate/severe allergic asthma. Am. Respir: Grit. Care Med. (2001) 163:A858.
   Google Scholar
• BUHL R, BEECH KM, BENSCH G et al: Rhumab-E25 (omalizumab, Xolair) Treatment allows sustained reduction of the need for inhaled corticosteroids in moderate/severe allergic asthma. 1. Allergy CBI]. Immuriol (2001) 107:s107.
   Google Scholar
• JUNIPER EF, GUYATT GH, FERRIE PJ etal.: Measuring quality of life in asthma. Am. Rev Respir. Dis. (1993) 147:832–838.
   PubMed Web of Science ®Google Scholar
• JUNIPER EF, GUYATT GH, WILLAN A etal.: Determining a minimal important change in a disease-specific Quality of Life Questionnaire. 1. Clin. Epidimiol (1994) 47:81–87.
   Google Scholar
• JUNIPER EF, GUYATT GH, FEENY DH etal.: Measuring quality of life in children with asthma. Qualin, Ilk Res. (1996) 5:35–46.
   Google Scholar
• WOLFE JD, THIRLWEL J: Omalizumab demonstrates inhaled corticosteroid (ICS) sparing in asthma across a range of disease severities. I Allergy OM. Immuriol (2001) 107:s107.
   Web of Science ®Google Scholar
• LANIER RQ, BUSSE W, CORREN P et al.: Long-term improvement in asthma control and exacerbation frequency is achieved with omalizumab (Xolair) in patients with moderate to severe asthma. Am. J. Respir. Grit. Care Med. (2001) 163:A858.
   Google Scholar
• HOLGATE S, CHUCHALIN A, HERBERT J etal.: Omalizumab (Xolair®, RhuMAb-E25), A novel therapy for severe allergic asthma. Am. I Respir: Grit. Care Med. (2001) 163:A812.
   Google Scholar
• HOLGATE S, CHUCHALIN A, HERBERT J etal.: Omalizumab, a novel therapy for severe allergic asthma. Eur. Respir J. (2001) 18:37s.
   Google Scholar
• HOLGATE S, CHUCHALIN A, HERBERT J etal.: Omalizumab (rhuMAb-E25) improves asthma specific quality of life in patients with severe allergic asthma. Am. Respir. Crir Care Med. (2001) 163:A858.
   Google Scholar
• HOLGATE S, CHUCHALIN A, HERBERT J et al: Omalizumab improves asthma-specific quality of life in patients with severe allergic asthma. Eur. Respir (2001) 18:37s.
   Google Scholar
• KAPSALI T, HOROWITZ E, DIEMER F et al.: Rhinitis is ubiquitous in allergic asthmatics. I Allergy Chi]. kunuriol. (1997) 99:S138. Abstract.
   Google Scholar
• PEDERSEN PA, WEEKE ER: Asthma and allergic rhinitis in the same patients. Allergy (1983) 38:25–29.
   PubMed Web of Science ®Google Scholar
• CORREN J: The impact of allergic rhinitison bronchial asthma. j Allergy Chi]. Inunuriol (1998) 101:S352–356.
   PubMed Web of Science ®Google Scholar
• CASALE T, CONDEMI J, MILLER SD: rhuMAB-E25 in the treatment of seasonal allergic rhinitis (SAM. Ann. Allergy Asthma Inunuriol (1999) 82:75. Abstract.
   Google Scholar
• CASALE TB, CONDEMI J, BERNSTEIN JA etal.: Safety of readministration of rhuMAb-E25 in seasonal allergic rhinitis. Ann. Allergy Asthma Inunuriol (2000) 84:125.
   Google Scholar
• HANF G, NOGA 0, O'CONNOR A et al.: Effect of humanized monoclonal anti-IgE antibody, omalizumab, on allergen challenge-induced nasal response in subjects with allergic rhinitis and allergic asthma. Eur. Respir j (2001) 18:36s.
   Google Scholar
• ADELROTH E, RAK S, HAAHTELA T et al.: Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. I Allergy CBI]. Inunuriol (2000) 106:253–259.
   PubMed Web of Science ®Google Scholar
• CHERVINSKYE BUSSE W, CASALE T et al.: Xolair ° in the treatment or perennial allergic rhinitis. j Allergy CBI]. Inunuriol. (2001) 107:513.
   Google Scholar
• CASALE T, CHERVINSKYP, BUSSE W et al.: Omalizumab in the treatment of perennial allergic rhinitis. Eur. Respir: (2001) 18:37s.
   Google Scholar
• ARSHAD SH, BABU KS, HOLGATE ST: Anti-IgE therapy in asthma and allergy. Martin Dunitz Ltd London: (2001).
   Google Scholar
• KUEHR J, ZIELEN S, SCHAUER U et al:Omaluzimab (Xolair®, RHUMAB-E25) in children with seasonal allergic rhinitis to birch and grass pollen: superior efficacy of Xolair ° plus specific immunotherapy over specific immunotherapy alone during grass pollen season. Allergy (2001) 56:93–94.
   Google Scholar
• WAHN U, ZIELEN S, SCHAUER U et al.: Omalizumab (Xolair®, rhuMAb-E25) plus specific immunotherapy in children with allergic rhinitis is superior to specific immunotherapy alone. Allergy (2001) 56:61.
   PubMedGoogle Scholar
• KOPP MV, RIEDINGER E BEISCHER D et al.: Combined effect of omaluzimab (RHUMAB-25, Xolair) and specific immunotherapy on in vitro leukotriene release. Allergy (2001) 56:93.
   Google Scholar
• OETTGEN HC, MARTIN TR, WYNSHAW-BORIS A etal.: Active anaphylaxis in IgE-deficient mice. Nature (1994) 370:367–370.
   Google Scholar
• SALVI SS, BABU KS: Treatment of allergicasthma with monoclonal anti-IgE antibody. N Erigl. J. Med. (2000) 342:1292-1293. Affiliation
   Google Scholar